Medco Research Institute and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications

Medco Research Institute LLC, a wholly owned subsidiary of Medco Health Solutions Inc. MHS, and AssureRx Health Inc. today announced the initiation of the PREDICT PSYMEDS pilot to evaluate antidepressant and antipsychotic drug adherence and medical care utilization by Medco members after being genotyped with AssureRx's GeneSightRx, a multi-gene pharmacogenetic profile test. GeneSightRx measures and analyzes multiple clinically important genetic variants that can help physicians understand the way a patient's unique genetic makeup affects his or her ability to tolerate or effectively respond to certain psychotropic medications.